Illumina, Inc. $ILMN Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. reduced its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 341,497 shares of the life sciences company’s stock after selling 17,431 shares during the period. Principal Financial Group Inc.’s holdings in Illumina were worth $32,432,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. UMB Bank n.a. increased its stake in Illumina by 10.5% during the third quarter. UMB Bank n.a. now owns 1,786 shares of the life sciences company’s stock worth $170,000 after acquiring an additional 169 shares during the last quarter. Transcend Capital Advisors LLC increased its stake in shares of Illumina by 34.4% in the third quarter. Transcend Capital Advisors LLC now owns 3,162 shares of the life sciences company’s stock worth $300,000 after buying an additional 810 shares during the last quarter. Keybank National Association OH raised its holdings in Illumina by 17.8% in the third quarter. Keybank National Association OH now owns 399,621 shares of the life sciences company’s stock valued at $37,952,000 after acquiring an additional 60,375 shares in the last quarter. National Pension Service lifted its position in shares of Illumina by 29.4% during the third quarter. National Pension Service now owns 46,284 shares of the life sciences company’s stock worth $4,396,000 after purchasing an additional 10,529 shares during the last quarter. Finally, AlphaQuest LLC lifted its holdings in Illumina by 181.4% during the 3rd quarter. AlphaQuest LLC now owns 1,559 shares of the life sciences company’s stock worth $148,000 after buying an additional 1,005 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Illumina

In related news, insider Scott M. Davies sold 323 shares of the stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the transaction, the insider directly owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.60% of the stock is owned by insiders.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q4 earnings beat — Illumina reported $1.35 GAAP/non‑GAAP EPS (beat consensus) and $1.16B in revenue (above estimates), showing 5% YoY revenue growth for the quarter. This confirms near‑term operating leverage and profitability. Zacks: Tops Q4 Estimates
• Positive Sentiment: FY2026 revenue guide lifted — Illumina gave 2026 revenue guidance of $4.5B–$4.6B (above Street revenue consensus), signaling expected mid-single-digit growth and underlying demand momentum. That revenue guide is a key upside catalyst for FY26. Press Release / Guidance
• Positive Sentiment: Operational tailwinds — Management highlighted clinical consumables growth, expansion into multiomics and margin momentum (non‑GAAP op margin guidance ~23.3–23.5%), supporting durable revenue mix improvement and higher-margin recurring revenue. Yahoo Deep Dive
• Neutral Sentiment: SomaLogic acquisition and dilution — Guidance includes ~$0.18 EPS dilution and ~100bps margin headwind from the recently closed SomaLogic deal; strategic for multiomics but a modest near‑term drag. PR Newswire: Financial Results
• Neutral Sentiment: Full call and disclosures available — The earnings call transcript, slide deck and SEC/press materials are posted for deeper review of segment trends and backlog — useful for modeling revenue cadence and margin drivers. Seeking Alpha Transcript
• Negative Sentiment: FY2025 revenue flat — Full-year 2025 revenue was essentially flat vs. 2024, a disappointment to some investors who had hoped for stronger recovery; this disappointment is the main reason shares are down despite the quarterly beat. Investing.com: Shares Tumble

Illumina Price Performance

Shares of Illumina stock opened at $133.61 on Friday. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $155.53. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43. The firm’s 50-day simple moving average is $138.67 and its 200-day simple moving average is $115.99. The firm has a market cap of $20.42 billion, a P/E ratio of 29.96, a price-to-earnings-growth ratio of 2.23 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same period in the prior year, the company earned $0.95 EPS. Illumina’s revenue for the quarter was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, research analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ILMN. Stifel Nicolaus upped their price objective on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Guggenheim increased their price target on Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Evercore ISI reiterated an “outperform” rating and issued a $155.00 price target on shares of Illumina in a research report on Monday, January 5th. TD Cowen reissued a “hold” rating on shares of Illumina in a research note on Wednesday, January 7th. Finally, Robert W. Baird set a $109.00 price objective on Illumina in a research note on Friday, October 31st. Six research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $127.18.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.